Skip to main content

Fiscal Wizard · Single-issue tearsheet

SILO / Jun 22, 2026 Run #7609

SILO

Silo Pharma, Inc.

Silo Pharma Inc. operates as a developmental stage biopharmaceutical company. The company is developing therapeutics that address underserved conditions, including post-traumatic stress disorder (PTSD), stress-induced anxiety disorders, fibromyalgia, and central nervous system (CNS) diseases. It focuses on developing traditional therapies and psychedelic treatments in formulations. The company's lead program, SPC-15, is an intranasal treatment targeting PTSD and stress-induced anxiety disorders. In addition, the company is developing SP-26, a time-release ketamine-loaded implant for fibromyalgia and chronic pain relief. In addition, the company's two preclinical programs comprise SPC-14, an intranasal compound for the treatment of Alzheimer's disease, and SPU-16, a CNS-homing peptide targeting multiple sclerosis (MS). The company's research and development programs are conducted through collaborations with Columbia University, Medspray Pharma BV, and the University of Maryland, Baltimore. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is based in Sarasota, Florida.

Composite verdict

F 17.8 / 100
Gated stand-aside 0 drivers · 6 gates blocking
Stand aside Setup or conviction grade does not support a directional trade.

Industry rank 303rd of 598 in Biotechnology

rescore-sweep
Technical synthesisRegime: volatile uptrend

No notable composite patterns — the signals don't cluster into a named setup right now.

Where value comes fromMargin of safety -55%

Earnings power doesn't cover the capital structure (high debt) — the EPV decomposition isn't meaningful for this name.

Fundamentals Weak

17.8 / 100

Score-bearing fundamentals shown here exclude gate-only risk checks. · 35 metrics shown.

Strongest
Weakest
Cash Conversion Cycle 100
Margin of Safety 0
EPS Growth (YoY) 100
Free Cash Flow Yield 0
P/B 75
FCF Margin 0

Technicals Unscored

/ 100

Stand aside — active guards gated the directional signals that fired. · 43 signals shown.

Risk Gates

6 blocking 4 caution

6 guards active, 43 signals gated.

Altman Z-Score Blocking

Bottom-band Altman Z blocks bullish signals — distress risk.

Interest Coverage Blocking

Weak interest coverage blocks bullish signals — debt-service risk.

Piotroski F-Score Blocking

Bottom-band Piotroski F blocks bullish signals — fundamental-quality risk.

MA Crossover Blocking

Blocks counter-regime signals only when the MA crossover agrees with the long-term regime.

Breakdown

Look under the hood

Empty pane

Pick a category, above, to crack it open.

Every chip in either subscore card drills into the metrics or signals that fed it — including the formula, the threshold band, and what the current reading means for SILO.